Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)

A Phase II Study of Nivolumab in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma

(2020) N. Nora Bennani et al.   BLOOD

Activity and Safety of Geptanolimab (GB226) for patients with unresectable, recurrent or metastatic alveolar soft part sarcoma: a phase 2 single-arm study

(2020) Yuankai Shi et al.   CLINICAL CANCER RESEARCH

Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study

(2019) Stephen M. Ansell et al.   JOURNAL OF CLINICAL ONCOLOGY

Safety and activity of sintilimab in patients with relapsed or refractory classical Hodgkin lymphoma (ORIENT-1): a multicentre, single-arm, phase 2 trial

(2019) Yuankai Shi et al.   Lancet Haematology

Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

(2019) John A. Thompson et al.   Journal of the National Comprehensive Cancer Network

Phase II Study of the PD-1 Inhibitor Pembrolizumab for the Treatment of Relapsed or Refractory Mature T-cell Lymphoma

(2019) Stefan K. Barta et al.   Clinical Lymphoma Myeloma & Leukemia

Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study

(2019) Radhakrishnan Ramchandren et al.   JOURNAL OF CLINICAL ONCOLOGY

Genomic Analyses of PMBL Reveal New Drivers and Mechanisms of Sensitivity to PD-1 Blockade

(2019) Bjoern Chapuy et al.   BLOOD

Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes

(2018) Poonam K. Panjwani et al.   HUMAN PATHOLOGY

Rapid Progression of Adult T-Cell Leukemia–Lymphoma after PD-1 Inhibitor Therapy

(2018) Lee Ratner et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma

(2017) Robert Chen et al.   JOURNAL OF CLINICAL ONCOLOGY

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China

(2017) Yuankai Shi et al.   Journal of Hematology & Oncology

PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis

(2017) Tim Wartewig et al.   NATURE

PD-1 Blockade in Mediastinal Gray-Zone Lymphoma

(2017) Christopher Melani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis

(2017) Peng-Fei Wang et al.   Frontiers in Pharmacology

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

(2016) S. H. Swerdlow et al.   BLOOD

DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China

(2016) X. Li et al.   CLINICAL CANCER RESEARCH

Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study

(2016) Alexander M. Lesokhin et al.   JOURNAL OF CLINICAL ONCOLOGY

Incidence of Programmed Cell Death 1 Inhibitor–Related Pneumonitis in Patients With Advanced Cancer

(2016) Mizuki Nishino et al.   JAMA Oncology

Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma

(2015) Y. Shi et al.   ANNALS OF ONCOLOGY

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study

(2015) Owen A. O'Connor et al.   JOURNAL OF CLINICAL ONCOLOGY

Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin

(2014) S. M. Horwitz et al.   BLOOD

Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification

(2014) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

High-dose therapy and autologous stem cell transplantation in peripheral T-cell lymphoma: treatment outcome and prognostic factor analysis

(2013) Lin Gui et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Hematopoietic Cell Transplantation for Systemic Mature T-Cell Non-Hodgkin Lymphoma

(2013) Sonali M. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Distribution of Lymphoid Neoplasms in China

(2012) Jian Sun et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Up-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01

(2012) Francesco d'Amore et al.   JOURNAL OF CLINICAL ONCOLOGY

Results From a Pivotal, Open-Label, Phase II Study of Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma After Prior Systemic Therapy

(2012) Bertrand Coiffier et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

(2011) R. L. Piekarz et al.   BLOOD

Pralatrexate in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results From the Pivotal PROPEL Study

(2011) Owen A. O'Connor et al.   JOURNAL OF CLINICAL ONCOLOGY

International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes

(2008)   JOURNAL OF CLINICAL ONCOLOGY

Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter Study

(2008) Peter Reimer et al.   JOURNAL OF CLINICAL ONCOLOGY